PhaseWell Research, a national clinical research site company, announced that it has formed a partnership with Bio Behavioral Health.
Bio Behavioral Health is a leading central nervous system research site focused on neurologic and psychiatric disorders. Based in Toms River, New Jersey, Bio Behavioral Health has deep expertise in conducting clinical trials in the community setting, with an emphasis on patient-centered care, data quality and efficient study execution.
Headquartered in Nashville, Tennessee, PhaseWell Research is focused on increasing participation in clinical trials by enabling research within trusted, high-performing sites and community practices nationwide.
The addition of Bio Behavioral Health strengthens PhaseWell’s growing network and enhances its capabilities in neurologic and psychiatric research. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this transaction represents the 12th Life Sciences R&D acquisition of the year, and the first in the clinical trial specialty. There were 23 clinical trial deals announced in 2025, 27 deals in 2024 and 42 deals in 2023.
